Precision macrophage targeting

Spica Therapeutics identifies and selectively targets disease-driving macrophage subsets to transform outcomes in oncology, fibroinflammatory and other chronic diseases.

Explore the platform View pipeline focus

The right macrophage target for the right patient and indication.

Patient derived single-cell data and proprietary computation reveal pathogenic macrophage fingerprints and actionable targets directly in human disease tissue

Discover the platform About Spica

Targeting disease-relevant macrophage biology in oncology and fibrosis.

Lead programs are designed around CD163 macrophage biology, translational datasets and patient-selection opportunities.

View pipeline Meet the team

HOMEPAGE PATHWAYS

A cleaner route into the company story.

About

A deep understanding of macrophage biology combined with clear therapeutic ambition.

Platform

Macrophage Fingerprinting Platform identifies patient-relevant targets for chronic diseases.

Pipeline

Initial lead programs focused on oncology and fibrosis.

Team

Built and led by scientific experts and experienced operators.

PLATFORM

Designed to identify disease specific macrophages and move from macrophage signal to therapeutic action

Human disease relevance

Patient-derived datasets guide target discovery and indication selection.

Differentiated assets

Lead antibody programs focus on disease-relevant CD163 macrophage biology.

Translational development

Biomarker and tracer concepts support patient selection and monitoring.

PIPELINE FOCUS

Initial programs focused on CD163 macrophage depletion

ONCOLOGY

Remodelling the tumor microenvironment.

FIBROSIS

Targeting macrophage-to-myofibroblast transition biology.

Tracer / Biomarker

Supporting patient selection and response monitoring.

NEWS & MEDIA

Latest company highlights.

December 2025

ST101 Selected for Clinical Development

August 2025

Spica Therapeutics Secures €1M VLAIO Grant

June 2025